Key Insights

Highlights

Success Rate

89% trial completion (above average)

Published Results

43 trials with published results (35%)

Research Maturity

92 completed trials (75% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

8.9%

11 terminated out of 123 trials

Success Rate

89.3%

+2.8% vs benchmark

Late-Stage Pipeline

46%

57 trials in Phase 3/4

Results Transparency

47%

43 of 92 completed with results

Key Signals

43 with results89% success11 terminated

Data Visualizations

Phase Distribution

98Total
Not Applicable (10)
P 1 (10)
P 2 (21)
P 3 (25)
P 4 (32)

Trial Status

Completed92
Terminated11
Unknown9
Not Yet Recruiting4
Recruiting4
Withdrawn2

Trial Success Rate

89.3%

Benchmark: 86.5%

Based on 92 completed trials

Clinical Trials (123)

Showing 20 of 20 trials
NCT07494045Phase 2Not Yet Recruiting

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

NCT06877247Phase 1CompletedPrimary

A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism

NCT03969329Phase 3RecruitingPrimary

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

NCT03633708Phase 3RecruitingPrimary

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT06434961Phase 3CompletedPrimary

The Trial of SHR6508 in Secondary Hyperparathyroidism

NCT05836220Phase 3CompletedPrimary

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2

NCT05832931Phase 3CompletedPrimary

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

NCT05543928Phase 3Terminated

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism

NCT05880914Recruiting

Precision Medicine Approaches to Renal Osteodystrophy

NCT00415584Phase 1TerminatedPrimary

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

NCT01167309Phase 1CompletedPrimary

LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients

NCT06130683Active Not RecruitingPrimary

Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism

NCT06126016Recruiting

A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.

NCT02133404Phase 2CompletedPrimary

A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

NCT06542315Not ApplicableNot Yet RecruitingPrimary

Intraoperative Parathyroid Hormone Monitoring to Guide Surgery in Renal hyperparathyroIdism

NCT06398002Phase 2Not Yet RecruitingPrimary

The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD

NCT06378931Not Yet RecruitingPrimary

Quality of Life Change in Patients Undergoing Parathyroidectomy With End-stage Renal Failure

NCT03937349CompletedPrimary

Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients

NCT06187480CompletedPrimary

Changes in Cardiac Functions in Patients Treated With Parathyroidectomy for Secondary Hyperparathyroidism

NCT01725113Phase 4Terminated

Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

Scroll to load more

Research Network

Activity Timeline